[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"influenza-prevention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:influenza-prevention":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100601483","phase-1-quadrivalent-influenza-ha-stem-vaccine-vrc-flumos0122-00-vp-stemos1-with-and-without-alfq-adjuvant-in-healthy-adults-100601483",false,"NCT07111078","Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults","VRC 329: A Phase I Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (STEMos1) With and Without ALFQ Adjuvant in Healthy Adults","* INCLUSION CRITERIA:\n\nA participant must meet all of the following criteria:\n\n* Healthy adults between the ages of 18-50 years, inclusive\n* Based on history and physical examination, be in good general health and without a history of any of the conditions listed in the exclusion criteria\n* Received at least one licensed influenza vaccine from the 2020-2021 influenza season through the 2024-2025 influenza season\n* Able and willing to complete the informed consent process\n* The ability to read and comprehend English as all consent and recruitment materials are in English.\n* Available for clinic visits for 68 weeks after the first dose, including through the 2025-2026 influenza season\n* Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process\n* Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) \\\u003C= 35 within the 56 days before enrollment\n* Agrees to not receive any licensed influenza vaccination during study participation due to potential confounding of study results\n* Willing to have blood and mucosal samples collected, stored indefinitely, and used for research purposes.\n\nLaboratory Criteria within 56 days before enrollment:\n\n* WBC and differential within institutional normal range or accompanied by approval of the site Principal Investigator (PI) or designee\n* Total lymphocyte count \\>= 800 cells\u002Fmicroliter\n* Platelets = 125,000-400,000 cells\u002Fmircoliter\n* Hemoglobin within institutional normal range or accompanied by approval of the PI or designee\n* Alanine aminotransferase (ALT) \\\u003C= 1.25 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) \\\u003C= 1.25 x institutional ULN\n* Alkaline phosphatase (ALP) \\\u003C 1.1 x institutional ULN\n* Total bilirubin within institutional normal range or accompanied by approval of the PI or designee\n* Serum creatinine \\\u003C= 1.1 x institutional ULN\n* Negative for HIV infection by an FDA-approved method of detection\n\nCriteria applicable to women of childbearing potential:\n\n* Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on the day of enrollment\n* Agrees to use an effective means of birth control from at least 21 days prior to enrollment through the end of the study\n\nEXCLUSION CRITERIA:\n\nParticipant will be excluded if one or more of the following conditions apply:\n\n-Women who are breast-feeding or planning to become pregnant during the study\n\nA participant has received any of the following substances:\n\n* Receipt of any licensed influenza vaccine or lab-confirmed influenza infection within 6 months prior to enrollment.\n* Plan to or are required to receive the 2025-2026 or 2026-2027 licensed influenza vaccines\n* Live attenuated vaccines within 4 weeks prior to enrollment\n* Inactivated vaccines within 2 weeks prior to enrollment\n* mRNA vaccines within 4 weeks prior to enrollment\n* Receipt of the HA ferritin influenza vaccine VRC-FLUNPF081-00-VP alone or in prime-boost regimens with VRC-FLUDNA082-00-VP (HA-F A\u002FSing, DNA A\u002FSing, VRC 316).\n* Receipt of the mosaic quadrivalent influenza vaccine VRC-FLUMOS0111-00-VP (FluMos-v1, VRC 325)\n* Receipt of the mosaic hexavalent influenza vaccine VRC-FLUMOS0116-00-VP (FluMos-v2, VRC 326)\n* More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment\n* Blood products within 16 weeks prior to enrollment\n* Investigational research agents within 4 weeks prior to enrollment or planning to receive investigational products while on the study\n* Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule\n* Current anti-TB prophylaxis or therapy\n\nParticipant has a history of any of the following clinically significant conditions:\n\n* Serious reactions to vaccines that preclude receipt of the study vaccinations as determined by the PI or designee\n* Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema\n* Asthma that is not well controlled\n* Diabetes mellitus (type I or II), except for gestational diabetes\n* Thyroid disease that is not well controlled\n* Idiopathic urticaria within the past year\n* Immune-mediated diseases, such as autoimmune or autoinflammatory diseases, or immunodeficiencies\n* Hypertension that is not well controlled\n* Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws\n* Malignancy that is active or history of malignancy that is likely to recur during the period of the study\n* Seizure disorder other than 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years\n* Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen\n* Guillain-Barr(SqrRoot)(Copyright) Syndrome\n* Any medical, social condition, occupational reason, or other reason that, in the judgment of the PI or designee, is a contraindication to protocol participation or impairs a participant's ability to give informed consent, including but not limited to clinically significant forms of infectious diseases, drug or alcohol abuse, autoimmune diseases, psychiatric disorders, or heart disease.",true,"ALL","18 Years","50 Years",{"count":21,"type":22},56,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Background:\n\nInfluenza (flu) is a contagious respiratory illness caused by viruses. Flu symptoms can range from mild to severe, and the illness can be fatal. Vaccines help the body learn to prevent or fight infections such as flu. Some vaccines are combined with adjuvants. Adjuvants are special salts or fats that help vaccines work better. Researchers are looking for ways to make flu vaccines more effective.\n\nObjective:\n\nTo test a new flu vaccine with and without a new adjuvant.\n\nEligibility:\n\nHealthy adults aged 18 to 50. They must have had at least 1 flu vaccine since 2020.\n\nDesign:\n\nParticipants will have 12 clinic visits over 15 months.\n\nThe vaccine is given as an injection into the muscle of the upper arm. Participants will be vaccinated during 2 visits spaced 4 months apart. Half will receive just the vaccine; half will receive the vaccine plus the adjuvant. They will be monitored for at least 30 minutes after each shot.\n\nParticipants will keep a diary for 7 days after each shot. They check their temperature every day and record any symptoms.\n\nParticipants will have 10 follow-up clinic visits plus 4 phone calls. They will have 4 to 10 tablespoons of blood drawn at each clinic visit. Fluid samples will be collected from their nose and mouth. They will be checked for any health changes.\n\nParticipants may opt to undergo apheresis: Blood will be taken from the body through a needle inserted into a vein. The blood will pass through a machine that separates out the white blood cells. The remaining blood will be returned to the body through a different needle.",[28,29],"Influenza Prevention","Pandemic Influenza Prevention",[31,32,33,34,35,36],"Dose-Escalation","INFLUENZA VIRUS","Immune Response","Respiratory Illness","Experimental Vaccine","Safety","RECRUITING","2026-08-19",{"date":40,"type":41},"2026-08-20","ACTUAL",{"date":43,"type":41},"2025-08-27",{"date":45,"type":22},"2027-08-18",{"name":47,"class":48},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100582425","phase-1-evaluating-the-dose-safety-tolerability-and-immunogenicity-of-mosaic-hexavalent-influenza-vaccine-vrcflumos0116-00-vp-flumos-v2-with-and-without-alfq-adjuvant-in-healthy-adults-100582425","NCT06863142","Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults","VRC 328: A Phase I Open-Label Clinical Trial to Evaluate the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults","* INCLUSION CRITERIA:\n* A participant must meet all of the following criteria:\n\n  * Healthy adults between the ages of 18-50 years, inclusive\n  * Based on history and physical examination, be in good general health and without a history of any of the conditions listed in the exclusion criteria\n  * Received at least one licensed influenza vaccine from the 2020-2021 influenza season through the 2024-2025 influenza season\n  * Able and willing to complete the informed consent process\n  * Available for clinic visits for 68 weeks after enrollment, including through the 2025-2026 influenza season\n  * Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process\n  * Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) \\\u003C= 35 within the 56 days before enrollment\n  * Agrees to not receive the 2025-2026 licensed influenza vaccination during study participation due to potential confounding of study results\n  * Willing to have blood and mucosal samples collected, stored indefinitely, and used for research purposes\n* Laboratory Criteria within 56 days before enrollment\n\n  * White blood cells (WBC) and differential within institutional normal range or accompanied by approval of the site Principal Investigator (PI) or designee\n  * Total lymphocyte count \\>= 800 cells\u002FmicroL\n  * Platelets = 125,000 - 400,000 cells\u002FmicroL\n  * Hemoglobin within institutional normal range or accompanied by approval of the PI or designee\n  * Alanine aminotransferase (ALT) \\\u003C= 1.25 x institutional upper limit of normal (ULN)\n  * Aspartate aminotransferase (AST) \\\u003C= 1.25 x institutional ULN\n  * Alkaline phosphatase (ALP) \\\u003C 1.1 x institutional ULN\n  * Total bilirubin within institutional normal range or accompanied by approval of the PI or designee\n  * Serum creatinine \\\u003C= 1.1 x institutional ULN\n  * Negative for HIV infection by an FDA-approved method of detection\n* Criteria applicable to women of childbearing potential:\n\n  * Negative beta-human chorionic gonadotropin (Beta-HCG) pregnancy test (urine or serum) on the day of enrollment\n  * Agrees to use an effective method of birth control from at least 21 days prior to enrollment through the end of the study.\n\nEXCLUSION CRITERIA:\n\n* A participant will be excluded if one or more of the following conditions apply:\n\n  \\-- Women who are breast-feeding or planning to become pregnant during the study\n* A Participant has received any of the following substances:\n\n  * Receipt of any licensed influenza vaccine within 6 months prior to enrollment.\n  * Plan to or are required to receive the 2025-2026 licensed influenza vaccine\n  * Live attenuated vaccines within 4 weeks prior to enrollment\n  * Inactivated vaccines within 2 weeks prior to enrollment\n  * mRNA vaccines within 4 weeks prior to enrollment\n  * Receipt of 20 mcg of the influenza vaccine VRC-FLUNPF081-00-VP (HA-F A\u002FSing, VRC 316, Group 1)\n  * Receipt of the mosaic quadrivalent influenza vaccine VRC-FLUMOS0111-00-VP (FluMos-v1, VRC 325)\n  * Receipt of the mosaic hexavalent influenza vaccine VRC-FLUMOS0116-00-VP (FluMos-v2, VRC 326)\n  * More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment\n  * Blood products within 16 weeks prior to enrollment\n  * Investigational research agents within 4 weeks prior to enrollment or planning to receive investigational products while on the study\n  * Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule\n  * Current anti-TB prophylaxis or therapy\n* Participant has a history of any of the following clinically significant conditions:\n\n  * Serious reactions to vaccines that preclude receipt of the study vaccinations as determined by the PI or designee\n  * Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema\n  * Asthma that is not well controlled\n  * Diabetes mellitus (type I or II), except for gestational diabetes\n  * Thyroid disease that is not well controlled\n  * Idiopathic urticaria within the past year\n  * Immune-mediated diseases, such as autoimmune or autoinflammatory diseases, or immunodeficiencies\n  * Hypertension that is not well controlled\n  * Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws\n  * Malignancy that is active or history of malignancy that is likely to recur during the period of the study\n  * Seizure disorder other than 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years\n  * Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen\n  * Guillain-Barre Syndrome\n  * Any medical, social condition, occupational reason, or other reason that, in the judgment of the PI or designee, is a contraindication to protocol participation or impairs a participant s ability to give informed consent, including but not limited to clinically significant forms of infectious diseases, drug or alcohol abuse, autoimmune diseases, psychiatric disorders, or heart disease.",{"count":58,"type":22},45,[25],"Background:\n\nVaccines help the body learn to fight infections. Some vaccines are combined with adjuvants, which are added substances that make vaccines work better. FluMos-v2 is an experimental flu vaccine; ALFQ is an experimental adjuvant.\n\nObjective:\n\nTo test FluMos-v2, with and without the ALFQ adjuvant, in healthy adults.\n\nEligibility:\n\nHealthy adults aged 18 to 50 years. They must have received at least one flu vaccine from the 2020-21 season through the 2024-25 flu season. They must also agree not to receive the licensed 2025-26 flu vaccine.\n\nDesign:\n\nParticipants will have 12 clinic visits over 15 months.\n\nParticipants will be screened. They will have a physical exam and blood tests.\n\nOn 2 visits, about 4 months apart, participants will receive a vaccination. The shots will be given into the muscle of the upper arm. They will get a follow-up call the day after each shot. They will keep a daily diary for 7 days; they will record their temperature and any other symptoms they feel after each shot.\n\nAll clinic visits will include collection of blood, saliva, and nasal secretions. If participants develop flu symptoms (such as fever, runny nose, sore throat), they will be asked to come to the clinic.\n\nAbout 2 weeks after each vaccination, participants may opt to undergo apheresis: Blood will be taken from the body through a needle inserted into one arm. The blood will pass through a machine that separates out the white blood cells. The remaining blood will be returned to the body through a needle in the other arm.",[28,62],"Seasonal Influenza",[64,33,65,34,35,66,67],"Dose - Escalation","Viral Infection","Experimental Adjuvant","Influenza Vaccine","2026-08-12",{"date":70,"type":41},"2026-08-13",{"date":72,"type":41},"2025-04-28",{"date":74,"type":22},"2027-02-09",{"name":47,"class":48},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":49},"100649240","phase-3-study-to-assess-the-prophylactic-efficacy-and-safety-of-sebaloxavir-marboxil-tabletsoral-suspension-for-influenza-prevention-in-household-contacts-aged-2-years-100649240","NCT07730346","Study to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets\u002FOral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets\u002FOral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.","Index Participants:\n\nInclusion Criteria：\n\n* 1\\. The index participant (aged ≥18 years), or the index participant (aged \\\u003C18 years) together with their legal guardian, understands and voluntarily provides written informed consent form (ICF). The index participant must be ≥1 year of age at the time of ICF signing, with no gender restriction.\n* 2\\. The index participant must be the first case of influenza virus infection in the household during the current influenza season.\n* 3\\. The index participant must have a positive result from a rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) assay.\n* 4\\. At the time of HHC randomization, the interval from the onset of the index participant's initial influenza symptoms to informed consent must be ≤48 hours. Symptom onset is defined as: first axillary temperature ≥37.5°C, or the presence of at least one other influenza symptom.\n* 5\\. The index participant must not have used any anti-influenza antiviral medications (including traditional Chinese medicines or Western medicines) since symptom onset, and must be willing to receive oseltamivir phosphate treatment after signing informed consent form.\n\nExclusion Criteria：\n\n* 1\\. Participants who are diagnosed with bacterial or other non-influenza virus infections at screening requiring systemic antibacterial or antiviral treatment;\n* 2\\. Participants with suspected hypersensitivity to the active ingredients or excipients of oseltamivir phosphate oral suspension\u002Fcapsules.\n\nHousehold contact:\n\nInclusion Criteria：\n\n* 1\\. Aged ≥2 years at the time of randomization, with no gender restriction;\n* 2\\. Has been living in the same household with the index participant for at least 48 hours at the time of randomization;\n* 3\\. Is able to reside with the index participant from screening\u002Frandomization through Day 10 (must live in the same household with the index participant for at least 7 days);\n* 4\\. Tests negative by rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR);\n* 5\\. Meets all of the following criteria and is judged by the investigator to have no influenza virus infection:\n\n  1. Axillary temperature \\\u003C37°C at screening;\n  2. No influenza-related symptoms at screening (such as nasal congestion, sore throat, cough, myalgia or arthralgia, fatigue, headache, chills\u002Fsweating, or other influenza symptoms assessed by the investigator);\n* 6\\. The HHC is ≥18 years of age, or the HHC is \\\u003C18 years of age and together with their parent(s)\u002Flegal guardian(s) understands and voluntarily signs the informed consent form (ICF), and agrees to comply with all study procedures, including completion of diary cards (the guardian may assist in assessment\u002Fcompletion).\n* 7\\. The HHC must sign the informed consent form (ICF) within 24 hours after the index participant signs the ICF;\n* 8\\. The HHC and their partner must agree to practice complete abstinence or use effective contraceptive measures from screening through 3 months after the end of study drug administration.\n\nExclusion Criteria：\n\n* 1\\. Participants with suspected hypersensitivity to the active pharmaceutical ingredients or excipients of the investigational product;\n* 2\\. Participants whose household contacts or other family members (excluding the index participant) have been diagnosed with influenza within 3 months before randomization;\n* 3\\. Participants who have been cohabiting with other family members exhibiting influenza-like symptoms (axillary temperature ≥37.5°C, nasal congestion, sore throat, cough, myalgia\u002Farthralgia, fatigue, headache, chills\u002Fsweating, or other influenza symptoms as assessed by the investigator) other than on the screening day;\n* 4\\. Participants requiring systemic (oral or injectable) or intranasal antipyretic\u002Fanalgesic agents, corticosteroids, or immunosuppressants (those using topical preparations are allowed);\n* 5\\. Participants who have received an influenza vaccine within 6 months prior to screening;\n* 6\\. Participants who have taken anti-influenza Chinese or Western medications within 30 days prior to screening, including but not limited to neuraminidase inhibitors, hemagglutinin inhibitors, M2 ion channel blockers, cap-dependent endonuclease (CEN) inhibitors, and heat-clearing\u002Fdetoxifying Chinese herbal medicines, such as oseltamivir, zanamivir, peramivir, laninamivir, umifenovir, favipiravir, rimantadine, amantadine, arbidol, nitazoxanide, baloxavir, Lianhua Qingwen capsules\u002Fgranules, Jinhua Qinggan granules\\*, etc.\n* 7\\. Participants with active infection or requiring systemic anti-infective treatment at screening (topical therapy for mild skin infections is allowed).\n* 8\\. Participants with other respiratory viral infections.\n* 9\\. Participants with difficulty swallowing study medication or a history of gastrointestinal disorders that may significantly impair drug absorption, including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, or post-gastrectomy.\n* 10\\. Participants with severe underlying comorbidities, defined as Grade 3 or higher per the Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0.\n* 11\\. Immunocompromised participants, including those with malignancies, history of organ or bone marrow transplantation, HIV infection, or use of immunosuppressants within the previous 3 months.\n* 12\\. HHCs requiring long-term use of aspirin- or salicylate-containing products, defined as daily regular use for more than 14 consecutive days.\n* 13\\. Participants with suspected or confirmed alcohol abuse (defined as weekly consumption of \\>14 units of alcohol; 1 unit = 360 mL beer, 45 mL of 40% spirits, or 150 mL of 12% wine) or history of drug abuse.\n* 14\\. Participants who have participated in another interventional clinical trial of a drug or medical device within 30 days before screening.\n* 15\\. Women who have a positive pregnancy test result or are currently lactating.\n* 16\\. Participants with any other conditions that, in the judgment of the investigator, would preclude enrollment in the study.","2 Years",{"count":85,"type":22},858,[87],"PHASE3","This study is a randomized, double-blind, placebo-controlled phase III clinical trial. The trial participants include index participants (IP) and household contacts (HHC). A total of 536 index participants (the first person in the household diagnosed with influenza) and 858 household contacts (family members living with the index participant) are planned to be enrolled. After the index participants and their household contacts have signed informed consent form and passed screening eligibility, randomization will be performed at the household level in a 1:1 ratio, stratifying by the time from onset of the index participant's initial influenza symptoms to signing of informed consent form (\\\u003C24 hours, ≥24 hours), index participant's viral subtype (influenza A, influenza B), and household contact's age (\\\u003C12 years, ≥12 years). Household contacts will be assigned to either the Sebaloxavir marboxil group or the placebo group. The study objective is to compare the prophylactic efficacy and safety of Sebaloxavir marboxil tablets\u002Foral suspension versus placebo in household contacts (HHCs).",[28],"NOT_YET_RECRUITING","2026-07-23",{"date":93,"type":41},"2026-07-28",{"date":95,"type":22},"2026-11-07",{"date":97,"type":22},"2028-01-30",{"name":99,"class":100},"Nanjing Zenshine Pharmaceuticals","INDUSTRY"]